PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal(University of the Witwatersrand), Daniel Gaudet(Brigham and Women's Hospital), Gisle Langslet(Oslo University Hospital), Traci Turner(Louisville Metabolic and Atherosclerosis Research Center), Anders Olsson(Linköping University), Ransi Somaratne(Amgen (United States)), Lesley Burgess(Stellenbosch University), Evan A. Stein(Oncotherapeutics (United States)), G. Kees Hovingh(Novo Nordisk (Denmark)), Robert Dufour(Myovant Sciences (United States)), Robert C. Scott(Amgen (United States)), Ioanna Gouni‐Berthold(University of Cologne), David Sullivan(Royal Prince Alfred Hospital), Fernando Civeira(Universidad de Zaragoza), Russell Scott(Camden and Campbelltown Hospitals), Scott M. Wasserman(Amgen (United States)), Ian Bridges(Amgen (United Kingdom)), Bertrand Cariou(Institut du Thorax)
Cited by 750
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k